IMVEXXY (estradiol) by Pfizer is estrogen receptor agonists [moa]. First approved in 2018.
Drug data last refreshed 4h ago · AI intelligence enriched 7h ago
IMVEXXY is a vaginal insert formulation of estradiol approved by FDA in May 2018 for the treatment of moderate-to-severe dyspareunia due to menopause-related vulvovaginal atrophy. It works as an estrogen receptor agonist, delivering localized hormone therapy directly to vaginal tissue. The product represents a novel delivery approach to a well-established active pharmaceutical ingredient.
Peak lifecycle status with modest $13M Part D spending indicates mature market penetration; brand team likely focused on retention and optimization rather than expansion.
Estrogen Receptor Agonists
Estrogen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Worked on IMVEXXY at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on IMVEXXY offers a stable, mature product environment with strong patent protection through 2034 and a specialized therapeutic niche. The peak-lifecycle status prioritizes commercial execution, market retention, and patient education over new indication development, making it suitable for professionals seeking established portfolio stability rather than launch-stage dynamism.